Agile Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
August 09, 2023 at 08:05 am EDT
Share
Agile Therapeutics, Inc. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported sales was USD 5.5 million compared to USD 2.13 million a year ago. Net loss was USD 3.81 million compared to USD 5.17 million a year ago. Basic loss per share from continuing operations was USD 2.15 compared to USD 57.29 a year ago.
For the six months, sales was USD 9.32 million compared to USD 3.89 million a year ago. Net loss was USD 9.2 million compared to USD 15.55 million a year ago. Basic loss per share from continuing operations was USD 6.85 compared to USD 203.76 a year ago.
Agile Therapeutics, Inc. is a women's healthcare company, which is engaged in fulfilling the unmet health needs of women. Its product and product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. Its initial product, Twirla, (levonorgestrel and ethinyl estradiol), a transdermal system, is a non-daily prescription contraceptive. Twirla is based on its proprietary transdermal patch technology, called Skinfusion, which is designed to allow drug delivery through the skin. Twirla (levonorgestrel and ethinyl estradiol) transdermal system is a once-weekly combined hormonal contraceptive (CHC) patch that contains the active ingredients levonorgestrel (LNG), a type of progestin, and ethinyl estradiol (EE), a type of estrogen. Its potential product pipeline consists of two types of product candidates: a progestin-only (P-only) contraceptive patch and potential Twirla line extensions.